 |
 |
 |
 |
 |
||
 |
||
 |
ON CANCER, |
|
|
||||
|
Two problems,
often the research has been funded by PHARMA, which in the drive for profits is eager to publicize bleeding with aspirin,
but not with the other NSAIDS. They often use lessons to suppor their findings;
however, these lesion are not a good The results are often contaminated by the use of other NSAIDs in addition to aspirin. These greatly increase the incident of gastrointestinal bleeding. For example a Madrid study (pre-publication edition on web, by Francisco J. De Abajo, MD, M.P.H, Division
de Farmacoepidemoligia y Farmacovigilamcia Agencia Espanola del Medicamento, Madrid found for 2,195 UGIC (upper gastrointestional
complications) that the concomitant use of aspirin with high does NSAIDs caused a 3 fold increase. “The concomitant use of low-does aspirin & NSAIDs at high does put patients at specially high
risk of UGIC. Published November of 2000. Another problem with PHARMA studies
are that they rely upon endoscopic examination for lesions, “However, it is known that these lesions are not good predictors
of major upper gastriointestional bleeding, yielding apparently opposite results” (at p. 4). Of interest was the find that there was no dose relationship in the 75 to 300 mg range. Since these are general taken for reduction of midocardio infractions.
It is my recommendation (JK) that the higher dose be taken so as to potentiate the cancer protective effect. r J Clin Pharmacol. 1991 Jul;32(1):77-83. |
||||
|
||||
|
Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Regular, high dosage usage
of aspirin for rheumatic disease; the ulcer incidents was only one fourth for those who took enteric aspirin.
Ann Intern Med. 1979 Oct;91(4):517-20.
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
Enter supporting content here
INTERNAL SITE SEARCH ENGINE by Google
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ |
||||